ciprofloxacin has been researched along with ruthenium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibañez, GA; Lozano, VA; Olivieri, AC | 1 |
| Fitzgerald Hughes, D; Marmion, CJ; Romero-Canelón, I; Sadler, PJ; Twamley, B; Ude, Z | 1 |
2 other study(ies) available for ciprofloxacin and ruthenium
| Article | Year |
|---|---|
Second-order analyte quantitation under identical profiles in one data dimension. A dependency-adapted partial least-squares/residual bilinearization method.
Topics: Algorithms; Chemistry Techniques, Analytical; Ciprofloxacin; Least-Squares Analysis; Linear Models; Luminescent Measurements; Organometallic Compounds; Ruthenium; Time Factors | 2010 |
A novel dual-functioning ruthenium(II)-arene complex of an anti-microbial ciprofloxacin derivative - Anti-proliferative and anti-microbial activity.
Topics: A549 Cells; Anti-Bacterial Agents; Antineoplastic Agents; Cations, Divalent; Cell Line, Tumor; Ciprofloxacin; Cisplatin; Coordination Complexes; Crystallography, X-Ray; Cymenes; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Escherichia coli; HCT116 Cells; Humans; Monoterpenes; Organometallic Compounds; Ruthenium; Tumor Suppressor Protein p53 | 2016 |